Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Relafen Consumer Litigation

In February 2002, a class-action lawsuit was filed in federal court in Massachusetts against GlaxoSmithKline PLC, SmithKline Beecham Corp, Beecham Group PLC, and SmithKline Beecham PLC, on behalf of consumers and third-party payors around the country who purchased the drug Relafen or its generic alternatives. The suit alleged the companies unlawfully obtained a patent which allowed them to enforce a monopoly over Relafen, causing consumers to pay inflated prices for the drug. A court in August 2001 ruled that GSK’s patent covering Relafen was both invalid and unenforceable due to the company’s inequitable conduct. In November 2004, the judge granted preliminary approval of a proposed settlement under which the defendant companies agreed to pay $75 million in damages.

Misconduct Type
Antitrust
Enforcement Agency
Non-Governmental
Contracting Party
None
Court Type
Civil
Disposition
Settlement
Date of Order
11/24/2004
Contractors Involved Penalty
Total
GlaxoSmithKline $75,000,000
Further Information Released
Law Firm Press Release 8/17/2007
Order 8/17/2007

Federal Contractor Misconduct Database